291 related articles for article (PubMed ID: 12819072)
1. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
Theilacker C; Coleman FT; Mueschenborn S; Llosa N; Grout M; Pier GB
Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072
[TBL] [Abstract][Full Text] [Related]
2. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.
Pier GB; DesJardin D; Grout M; Garner C; Bennett SE; Pekoe G; Fuller SA; Thornton MO; Harkonen WS; Miller HC
Infect Immun; 1994 Sep; 62(9):3972-9. PubMed ID: 8063415
[TBL] [Abstract][Full Text] [Related]
3. Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins.
Pier GB; Grout M; Desjardins D
J Immunol; 1991 Sep; 147(6):1869-76. PubMed ID: 1832427
[TBL] [Abstract][Full Text] [Related]
4. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
Pier GB
Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate.
Kashef N; Behzadian-Nejad Q; Najar-Peerayeh S; Mousavi-Hosseini K; Moazzeni M; Djavid GE
J Med Microbiol; 2006 Oct; 55(Pt 10):1441-1446. PubMed ID: 17005795
[TBL] [Abstract][Full Text] [Related]
6. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients.
Meluleni GJ; Grout M; Evans DJ; Pier GB
J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254
[TBL] [Abstract][Full Text] [Related]
7. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From
Sen-Kilic E; Blackwood CB; Boehm DT; Witt WT; Malkowski AC; Bevere JR; Wong TY; Hall JM; Bradford SD; Varney ME; Damron FH; Barbier M
Front Immunol; 2019; 10():2497. PubMed ID: 31708925
[No Abstract] [Full Text] [Related]
8. Induction of opsonic antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide by an anti-idiotypic monoclonal antibody.
Schreiber JR; Pier GB; Grout M; Nixon K; Patawaran M
J Infect Dis; 1991 Sep; 164(3):507-14. PubMed ID: 1831226
[TBL] [Abstract][Full Text] [Related]
9. Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa.
Pier GB; Takeda S; Grout M; Markham RB
J Clin Invest; 1993 Mar; 91(3):1079-87. PubMed ID: 8450038
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.
Campodónico VL; Llosa NJ; Bentancor LV; Maira-Litran T; Pier GB
Infect Immun; 2011 Aug; 79(8):3455-64. PubMed ID: 21628521
[TBL] [Abstract][Full Text] [Related]
11. Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa.
Farjah A; Owlia P; Siadat SD; Mousavi SF; Ardestani MS; Mohammadpour HK
APMIS; 2015 Feb; 123(2):175-83. PubMed ID: 25470757
[TBL] [Abstract][Full Text] [Related]
12. Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide.
Garner CV; DesJardins D; Pier GB
Infect Immun; 1990 Jun; 58(6):1835-42. PubMed ID: 2140341
[TBL] [Abstract][Full Text] [Related]
13. Conjugation of alginate to a synthetic peptide containing T- and B-cell epitopes as an induction for protective immunity against Pseudomonas aeruginosa.
Farjaha A; Owlia P; Siadat SD; Mousavi SF; Shafieeardestani M
J Biotechnol; 2014 Dec; 192 Pt A():240-7. PubMed ID: 25449544
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine.
Cryz SJ; Fürer E; Que JU
Infect Immun; 1991 Jan; 59(1):45-50. PubMed ID: 1898901
[TBL] [Abstract][Full Text] [Related]
15. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).
Hatano K; Goldberg JB; Pier GB
Infect Immun; 1995 Jan; 63(1):21-6. PubMed ID: 7528730
[TBL] [Abstract][Full Text] [Related]
16. Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.
Hatano K; Boisot S; DesJardins D; Wright DC; Brisker J; Pier GB
Infect Immun; 1994 Sep; 62(9):3608-16. PubMed ID: 7520416
[TBL] [Abstract][Full Text] [Related]
17. Antibody to Pseudomonas aeruginosa mucoid exopolysaccharide and to sodium alginate in cystic fibrosis serum.
Speert DP; Lawton D; Mutharia LM
Pediatr Res; 1984 May; 18(5):431-3. PubMed ID: 6233529
[TBL] [Abstract][Full Text] [Related]
18. Polysaccharide antigens of Pseudomonas aeruginosa.
Pier GB
Rev Infect Dis; 1988; 10 Suppl 2():S337-40. PubMed ID: 3142017
[TBL] [Abstract][Full Text] [Related]
19. Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains.
Hatano K; Pier GB
Infect Immun; 1998 Aug; 66(8):3719-26. PubMed ID: 9673254
[TBL] [Abstract][Full Text] [Related]
20. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG.
Alonso de Velasco E; Verheul AF; van Steijn AM; Dekker HA; Feldman RG; Fernández IM; Kamerling JP; Vliegenthart JF; Verhoef J; Snippe H
Infect Immun; 1994 Mar; 62(3):799-808. PubMed ID: 7509318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
